Information regarding the Yupelri package insert can be found through various sources. The U.S. Food and Drug Administration (FDA) provides access to approved drug labeling. Additionally, drug information databases often compile and present this information.
What is Yupelri used for?
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is administered once daily via a nebulizer.
Where can I find the official Yupelri package insert?
The official package insert for Yupelri can typically be accessed on the U.S. Food and Drug Administration's (FDA) website. Pharmaceutical companies also make prescribing information available on their respective drug websites.
When does Yupelri's patent expire?
Information regarding patent expiration for Yupelri can be found through resources like DrugPatentWatch.com [1]. These resources track patent filings, grants, and expiration dates, which are crucial for understanding market exclusivity.
Are there other treatments for COPD airflow obstruction?
Yes, other treatments for COPD airflow obstruction include other LAMAs, long-acting beta-agonists (LABAs), and inhaled corticosteroids (ICS), often used in combination therapies. The choice of treatment depends on the individual patient's needs and disease severity.